新一代抗菌药物Dalbavancin的研究进展

Advances in Research of a New Antibiotics Dalbavancin

关键词:  Dalbavancin  抗菌药  药动学  药效学

Key words:  Dalbavancin  antibacterial  pharmacokinetics  pharmacodynamics

摘要:

目的 综述新一代抗菌药物Dalbavancin的最新研究进展。 方法 通过检索Google Scholar以及Science Direct查阅大量近10年的相关文献，对Dalbavancin抗菌机制、抗菌活性、药动学、药效学以及安全性多角度综述分析。结果 Dalbavancin是一种糖肽类浓度依赖性抗菌药物，其体内外抗耐甲氧西林葡萄球菌(MIC50=0.06 mg·L^-1)的活性明显优于万古霉素(MIC50=1 mg·L^-1)、替考拉宁(MIC50=0.5 mg·L^-1)；其临床药动学表明具有每周给药1次的潜力，体内有效治疗浓度为20 mg·L^-1。结论 Dalbavancin是一种菌体耐药性突变率低，不良反应温和，药物毒性较小处于临床Ⅲ期研究的最具应用价值的新一代抗菌药物。

Abstract:

OBJECTIVE To introduce advances in research of a new antibiotics Dalbavancin. METHODS Based on the correlative materials of recent 10 year searched from the data base of Google Scholar and Science Direct, the antibacterial mechanism, the antibacterial activity, the pharmacokinetics, the pharmacodynamics and drug safety of Dalbavancin had been briefly summarized overlaying multiple perspectives. RESULTS Dalbavancin is a concentration-dependent antibiotic of glycopeptides. The antibacterial activity in vivo and vitro of Dalbavancin with low bacteria resistance mutation rate, mild untoward effect and low drug toxicity(MIC50=0.06 mg·L^-1) is obviously superior to vancomycin(MIC50=1 mg·L^-1) and teicoplanin(MIC50=0.5 mg·L^-1); The clinical pharmacokinetics of Dalbavancin indicated the potential of administration once-weekly and the effective treatment concentration is 20 mg·L^-1. CONCLUSION Dalbavancin is a lower bacteria resistance mutation rate, moderate adverse reactions and lower drug toxicity new antibiotics with most application value in phase Ⅲ clinical studies.